ReviewCurrent opinion in infectious diseases2011
Immune responses against Aspergillus fumigatus: what have we learned?
Review in Current opinion in infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 96 citations in OpenAlex.
- Aneuploidy promotes transient stress adaptation and metabolic flexibility in the human fungal pathogen Aspergillus fumigatus.Current biology : CB · 2026Article
- Human natural killer cells exhibit potent antifungal activity against azole-resistantMicrobiology spectrum · 2026Article
- Emerging Applications of Triazole Antifungal Drugs.International journal of molecular sciences · 2026Review
- Fungal Infections in Pediatric Patients With Hematologic Malignancies and Stem Cell Transplantation: Impact on the Upper and Lower Respiratory Systems.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Molecular mechanisms drivingFrontiers in molecular biosciences · 2026Review
- Angioinvasion severity and admission GCS predict outcomes in invasive central nervous system fungal infections.Frontiers in cellular and infection microbiology · 2026Article
- Aspergillus pseudomembranous tracheitis leading to tracheal cartilage exfoliation: uncommon disease with rare presentation.BMC infectious diseases · 2025Article
- Whole-chromosome duplications drive antimicrobial resistance inbioRxiv : the preprint server for biology · 2025Article
- Pilot Study Comparing the In Vitro Response of Circulating Monocytes toJournal of fungi (Basel, Switzerland) · 2025Article
- Aspergillus fumigatus is responsible for inflammation in a murine model of chronic obstructive pulmonary disease exacerbation.Respiratory research · 2025Article
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
- Interplay of Cytokines and Chemokines in Aspergillosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Prevalence, Risk Factors, and Mortality of Invasive Pulmonary Aspergillosis in Patients with Anti-MDA5+ Dermatomyositis: A Retrospective Study in China.Journal of inflammation research · 2024Article
- Drug-ResistantPathogens (Basel, Switzerland) · 2023Review
- Problems Encountered Using Fungal Extracts as Test Solutions for Fungal Allergy Diagnosis.Journal of fungi (Basel, Switzerland) · 2023Review
- Characterization of Lung Inflammatory Response toJournal of fungi (Basel, Switzerland) · 2023Article
- Targeting the Granulocytic Defense againstInternational journal of molecular sciences · 2023Article
- Navigating the challenges of invasive pulmonary aspergillosis in lung cancer treatment: a propensity score study.Therapeutic advances in medical oncology · 2023Article
- Serum Cytokine Biomarkers for Use in Diagnosing Pulmonary Tuberculosis versus Chronic Pulmonary Aspergillosis.Infection and drug resistance · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewAspergillus fumigatus causes invasive and allergenic disease. Host defense relies on the ability of the respiratory immune system to restrict spore germination into invasive hyphae and to limit fungus-induced or inflammation-induced damage in infected tissues. This review covers the molecular and cellular events that mediate innate and CD4 T-cell responses to A. fumigatus and fungal attributes that counter hostile microenvironments and, in turn, affect host responses. RECENT
findingsHost recognition of fungal cell wall components is critical for fungal uptake, killing, and the formation of protective innate and CD4 T-cell effector populations. Beyond the known role of neutrophils and macrophages, circulating monocytes, dendritic cells, and natural killer cells contribute to optimal defense against A. fumigatus. Genetic and pharmacologic manipulation of A. fumigatus reveals that hypoxia adaptation, cell wall assembly, and secondary metabolite production in mammalian tissues contribute to fungal pathogenesis and the outcome of infection. SUMMARY: Greater understanding of the immune mechanisms that underlie protective responses and fungal pathways that promote microbial adaptation and growth in mammalian tissue provide a conceptual framework for improving current antifungal therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.